Sutro Biopharma - Asset Resilience Ratio
Sutro Biopharma (STRO) has an Asset Resilience Ratio of 48.49% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read STRO current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Sutro Biopharma's Asset Resilience Ratio has changed over time. See what is Sutro Biopharma's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Sutro Biopharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see STRO market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $101.67 Million | 48.49% |
| Total Liquid Assets | $101.67 Million | 48.49% |
Asset Resilience Insights
- Very High Liquidity: Sutro Biopharma maintains exceptional liquid asset reserves at 48.49% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Sutro Biopharma Industry Peers by Asset Resilience Ratio
Compare Sutro Biopharma's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Sutro Biopharma (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Sutro Biopharma.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 32.69% | $126.59 Million | $387.21 Million | -32.39pp |
| 2023-12-31 | 65.08% | $306.35 Million | $470.74 Million | -5.47pp |
| 2022-12-31 | 70.55% | $287.11 Million | $406.94 Million | +21.48pp |
| 2021-12-31 | 49.07% | $167.52 Million | $341.41 Million | +7.97pp |
| 2020-12-31 | 41.10% | $161.99 Million | $394.11 Million | -31.10pp |
| 2019-12-31 | 72.20% | $112.90 Million | $156.37 Million | +36.71pp |
| 2018-12-31 | 35.49% | $79.19 Million | $223.14 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $40.77 Million | -- |
| 2016-12-31 | 51.86% | $35.93 Million | $69.28 Million | -- |
About Sutro Biopharma
Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid … Read more